Evidence map›Paper›PMID 29761157›Full record

ReviewAcademic pathology

A Next-Generation Sequencing Primer-How Does It Work and What Can It Do?

Yuriy O Alekseyev, Roghayeh Fazeli, Shi Yang, Raveen Basran, Thomas Maher, Nancy S Miller, Daniel Remick

Open access · goldAbstract readReview
In one paragraph

Review in Academic pathology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 95 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. What Whole Genome Sequencing Has Told Us About Pathogenic Vibrios.Advances in experimental medicine and biology · 2023
    Review
  7. Article
  8. Article
  9. Article
  10. MRD in ALL: Optimization and Innovations.Current hematologic malignancy reports · 2022
    Review
  11. Review
  12. DisseminatedAnnals of translational medicine · 2022
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Case Report: AFrontiers in medicine · 2021
    Article
  20. Case Report:Frontiers in cardiovascular medicine · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yuriy O AlekseyevDepartment of Pathology and Laboratory Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.
Roghayeh FazeliDepartment of Pathology and Laboratory Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.
Shi YangDepartment of Pathology and Laboratory Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.
Raveen BasranDepartment of Pathology and Laboratory Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.
Thomas MaherDepartment of Pathology and Laboratory Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.ORCID 0000-0002-6083-9487
Nancy S MillerDepartment of Pathology and Laboratory Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.
Daniel RemickDepartment of Pathology and Laboratory Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.ORCID 0000-0002-2615-3713
Boston University · US

Funding

Impact of Biological, Clinical, and Social Determinants on Trauma and Trauma OutcomesT32GM086308 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Alik Farber, Daniel G. Remick · 2010 to 2026
$3.5M
Mechanisms of phagocytic cell defects induced by inhibitory IgGR21AI112887 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI REMICK, DANIEL G. · 2014 to 2015
$450k
Mechanisms of augmented host defenses after mild brain injuryR01GM117519 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI REMICK, DANIEL G. · 2017 to 2017
$247k
NIAID NIH HHS R21 AI112887NIGMS NIH HHS R01 GM117519NIGMS NIH HHS T32 GM086308
6 · The paper itself

Abstract

Next-generation sequencing refers to a high-throughput technology that determines the nucleic acid sequences and identifies variants in a sample. The technology has been introduced into clinical laboratory testing and produces test results for precision medicine. Since next-generation sequencing is relatively new, graduate students, medical students, pathology residents, and other physicians may benefit from a primer to provide a foundation about basic next-generation sequencing methods and applications, as well as specific examples where it has had diagnostic and prognostic utility. Next-generation sequencing technology grew out of advances in multiple fields to produce a sophisticated laboratory test with tremendous potential. Next-generation sequencing may be used in the clinical setting to look for specific genetic alterations in patients with cancer, diagnose inherited conditions such as cystic fibrosis, and detect and profile microbial organisms. This primer will review DNA sequencing technology, the commercialization of next-generation sequencing, and clinical uses of next-generation sequencing. Specific applications where next-generation sequencing has demonstrated utility in oncology are provided.

Indexed as

diagnostic testmicrobiologymutationoncologysequencing

Identifiers

PMID29761157
PMCPMC5944141
OpenAlexW2802423463

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.